Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Pretreatment (baseline) and posttreatment chemokine levels in responders and nonresponders. P values were determined by analysis of variance (ANOVA) for repeated measures

From: Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study

  Responders Nonresponders
  mean ± SD p value mean ± SD p value
CXCL10 (pg/ml)
 Pretreatment 605.5 ± 580.6 0.01* 283.2 ± 265.1 0.04*
 Posttreatment 411.1 ± 458.3 218.4 ± 237.3
CXCL13 (pg/ml)
 Pretreatment 382.7 ± 644.3 <0.0001* 26.7 ± 23.8 0.86
 Posttreatment 90.6 ± 128.2 35.7 ± 46.8
CCL20 (pg/ml)
 Pretreatment 13.6 ± 12.7 0.003* 19.0 ± 31.0 0.047*
 Posttreatment 6.9 ± 8.9 7.2 ± 7.2
  1. CXCL10 C-X-C motif chemokine 10, CXCL13 C-X-C motif chemokine 13, CCL20 C-C motif chemokine 20
  2. *p < 0.05